Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huda Salman

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Oncotarget|February 28, 2018
<i>SALL1</i> expression in acute myeloid leukemiaHuda Salman, Xiao Shuai, Anh Thu Nguyen-Lefebvre, et al.
Oncotarget|May 23, 2015
RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemiaAustin Y Shull, Satish K Noonepalle, Farrukh T Awan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2015
Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsXiaoyun Lu, Zhi-Chun Ding, Yang Cao, et al.
Oncotarget|August 6, 2016
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignanciesKevin H Chen, Masayuki Wada, Amelia E Firor, et al.
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Cancer Discovery|November 27, 2024
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular AlterationsMei Luo, Jingwen Yang, Alejandro A Schäffer, et al.
Oncotarget|January 20, 2018
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cellsKevin G Pinz, Elizabeth Yakaboski, Alexander Jares, et al.
Leukemia|March 9, 2018
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemiaJessica C Petrov, Masayuki Wada, Kevin G Pinz, et al.
NPJ Precision Oncology|February 26, 2026
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AMLSanthosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, et al.
Critical Care Medicine|April 19, 2021
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized TrialElliott Bennett-Guerrero, Jamie L Romeiser, Lillian R Talbot, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Oncotarget|February 28, 2018
<i>SALL1</i> expression in acute myeloid leukemiaHuda Salman, Xiao Shuai, Anh Thu Nguyen-Lefebvre, et al.
Oncotarget|May 23, 2015
RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemiaAustin Y Shull, Satish K Noonepalle, Farrukh T Awan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2015
Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsXiaoyun Lu, Zhi-Chun Ding, Yang Cao, et al.
Oncotarget|August 6, 2016
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignanciesKevin H Chen, Masayuki Wada, Amelia E Firor, et al.
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Cancer Discovery|November 27, 2024
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular AlterationsMei Luo, Jingwen Yang, Alejandro A Schäffer, et al.
Oncotarget|January 20, 2018
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cellsKevin G Pinz, Elizabeth Yakaboski, Alexander Jares, et al.
Leukemia|March 9, 2018
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemiaJessica C Petrov, Masayuki Wada, Kevin G Pinz, et al.
NPJ Precision Oncology|February 26, 2026
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AMLSanthosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, et al.
Critical Care Medicine|April 19, 2021
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized TrialElliott Bennett-Guerrero, Jamie L Romeiser, Lillian R Talbot, et al.
Pageof 4